The Fly

AstraZeneca to present haematology portfolio and pipeline at ASH 2022

The company states: "AstraZeneca will present 47 abstracts showcasing new data from across its haematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology Annual Meeting and Exposition, 10 to 13 December 2022. A total of eight approved and potential new medicines will be featured across more than ten types of blood cancers and rare diseases, including data in chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome and amyloid light chain amyloidosis." Reference Link

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AZN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More